Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes (T2D) and obesity, but growing attention has been directed toward gallbladder complications reported during therapy.¹ Given their cardioprotective effects, expanded approved disease management indications, and generally tolerable safety profile, the use of medications such as semaglutide, liraglutide, and dulaglutide continues to increase. However, there are concerns regarding an increased risk of gastrointestinal and hepatobiliary adverse effects, including gallbladder-related events such as cholelithiasis (gallstones) and cholecystitis, observed in clinical trials and reported in the FDA Adverse Event Reporting System (FAERS).^1-3 Per FAERS data, semaglutide was among the top 5 drugs associated with cholelithiasis, cholecystitis, and acute cholecystitis.⁴

Notably, differences among GLP-1 RA brands and doses have been observed in gallbladder complication incidence rates.^5-7

Gallbladder disease includes various hepatobiliary complications, such as cholecystitis and cholelithiasis.⁸ Gallstone formation is a multifactorial process influenced by patient-specific and treatment-related factors that disrupt normal gallbladder function and bile homeostasis.⁹ Obesity and rapid weight loss are risk factors for gallbladder disease.⁸ The expansion of liraglutide and semaglutide FDA indications to include obesity management in 2014 and 2021, respectively, is largely attributable to their significant contribution to weight loss in clinical practice.¹

Consequently, obesity and GLP-1 RA–associated weight loss have been proposed as contributing factors to the increased incidence of gallbladder disease.⁶ Although clinically significant weight loss occurs in patients receiving GLP-1 RA therapy across indications other than obesity treatment, such as T2D, this weight loss may also play a role in the development of GLP-1 RA–associated gallbladder disease. Evidence indicates that the risk of GLP-1 RA–associated gallbladder disease may be drug-specific and affected by the duration of therapy, dose of medication, and degree of weight loss.^5-7

Clinical Evidence and Possible Molecular Mechanisms of
GLP-1 RA–Associated Gallbladder Disease

Overall, evidence from clinical trials, meta-analyses, and observational studies has shown an increased incidence of gallbladder-related adverse events in patients on GLP-1 RA therapy, as summarized in the Table. The association appears to be strongest with longer treatment duration, higher doses, and obesity treatment populations compared with T2D populations. Although most evidence focuses on liraglutide, studies suggest that gallbladder disease may be a class effect of GLP-1 RAs, possibly linked to weight loss.

GLP-1 RAs promote metabolic health and weight loss in part through delayed gastric emptying and regulation of gut hormones, thereby enhancing satiety and reducing caloric intake.¹⁰ Because GLP-1 RAs delay gastric emptying, nutrient delivery to the distal ileum is also delayed; this may lead to decreased release of fibroblast growth factor 19 (FGF19), a key gut hormone that regulates bile acid synthesis.¹¹

Delayed gastric emptying is associated with a prolonged time to reach the maximum postprandial gallbladder ejection fraction (GBEF_max), indicating slowed gallbladder emptying after a meal.¹² Prolonged gallbladder emptying extends bile residency, whereas reduced FGF19 secretion increases cholesterol saturation within the bile. GLP-1 RAs have also been shown to decrease gallbladder relaxation, bile acid secretion, and motility by decreasing farnesoid X receptor (FXR) and Takeda G protein–coupled receptor 5 (TGR5) signaling. Combined, these mechanisms create an environment that allows cholesterol crystals to form, potentially leading to cholelithiasis.¹

FXR is responsible for increasing bile salt export pump (BSEP) expression, which facilitates the transport of bile acids from the liver into bile for normal bile flow. With less BSEP expression, the bile acids are not secreted as efficiently, and the concentration of cholesterol in the bile increases, leading to gallstone formation due to biliary stasis. TGR5, when activated, prevents biliary stasis and regulates normal gallbladder function. When TGR5 signaling is reduced via GLP-1 RA use, gallstones can also form due to biliary stasis.¹

GLP-1 RAs have also been shown to reduce GLP-2, a gut hormone involved in gallbladder relaxation and refilling, which may further impair biliary homeostasis.¹³ Gallbladder emptying is primarily regulated by cholecystokinin (CCK), which promotes contraction and release of bile into the small intestine.^1,13 Although there may be conflicting evidence on whether GLP-1 RAs increase or decrease CCK activity, altered CCK signaling may contribute to bile stasis and poor digestion, leading to gallstone formation.^13,14

The Pharmacist’s Role in Counseling and Monitoring

Pharmacists, being among the most accessible health care providers, can help minimize the risk of gallbladder complications in patients receiving GLP-1 RA therapy. Assessing preexisting risk factors such as female sex, dyslipidemia, and use of estrogen-containing oral contraceptives is an important first step.¹⁹ Because weight loss and gallbladder disease are known effects of GLP-1 RA therapy, it is vital to counsel patients on recognizing the symptoms of gallbladder complications and on the appropriate use of GLP-1 RAs. In FAERS reporting, cholelithiasis was among the top 5 drug-related conditions, with semaglutide among the top 5 drugs reported, out of 36,302 total cases.⁴ Reducing the risk of gallstones can include gradual, sustained weight loss through dietary modifications—specifically avoiding overly restrictive low-fat diets—and encouraging daily exercise.²⁰

Patient counseling should differentiate between common gastrointestinal effects of GLP-1 RA use and warning signs of gallbladder disease, as shown in the Figure. Because the initial presentation of gallbladder disease can be mistaken for routine gastrointestinal intolerance symptoms, such as nausea, diarrhea, constipation, and vomiting, patient education is of utmost importance.²¹ Recognizing differences in the characteristics, timing, and severity of symptoms is essential for early recognition and appropriate medical referral. Patients should also be counseled on lifestyle strategies, including eating smaller, more frequent meals; limiting high-fat foods; avoiding rapid weight loss without medical supervision; and engaging in regular physical activity.^22,23 Unlike the expected transient gastrointestinal adverse effects of GLP-1 RA therapy, gallbladder disease is more likely to present with persistent pain and other concerning symptoms that can occur at any point during therapy or after significant weight loss.²⁴ It is also notable that long-acting agents such as liraglutide and dulaglutide, vs short-acting agents such as exenatide, have shown a lower incidence of nausea and vomiting but a higher occurrence of diarrhea.²⁵

Community pharmacists are often among the first health care professionals to counsel patients starting GLP-1 RA therapy and are therefore well positioned to discuss the risks and to identify patients whose predisposing factors place them at an even higher risk of gallstones. Clinical pharmacists also play an important role in interdisciplinary collaboration with physicians when evaluating patients with gallbladder complications. As medication experts, pharmacists can educate prescribers on emerging evidence linking GLP-1 RAs to gallbladder disease, thereby assisting with patient-specific, treatment-based risk assessment.

Conclusion

As GLP-1 RA use expands over multiple indications, further research is needed to evaluate the long-term risk of gallbladder disease. The expansion of resources should focus on patient-specific risk assessment, identifying high-risk populations, and developing prevention and monitoring strategies for these high-risk individuals. Pharmacists play an important role in educating patients and other health care professionals on safe and effective use of GLP-1 RAs to improve medication safety outcomes.

About the Authors

Brittany Grammas, MMS, PharmD Candidate 2028, is a second-year PharmD candidate at South College School of Pharmacy and serves as president of the Student Society of Health-System Pharmacists. She is passionate about pursuing postgraduate residency training and advancing patient care through clinical practice, research, and pharmacy leadership.

Abraham Padilla, BS, PharmD Candidate 2028, is a second-year PharmD candidate at South College School of Pharmacy and serves as the treasurer of the Student National Pharmaceutical Association. He is passionate about returning to underserved communities and wishes to pursue a residency in ambulatory care to educate and treat local communities.

Maha Abdalla, PharmD, PhD, RPh, is the director of health affairs at South College School of Pharmacy and a pharmacist‑researcher focused on molecular and translational research in cardiopulmonary diseases, advancing patient advocacy, and promoting health equity.

REFERENCES

1. Ramírez-Mejía MM, Ponciano-Rodriguez G, Eslam M, Méndez-Sánchez N. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications. Ther Adv Endocrinol Metab. 2025;16:20420188251406456. doi:10.1177/20420188251406456

2. Eldesouki MH, Alkasabrah O, Kloub M, et al. Cohort study: risk of gallstones and biliary complications with glucagon‐like peptide‐1 receptor agonists in type 2 diabetes. United European Gastroenterol J. 2026;14(5):e70238. doi:10.1002/ueg2.70238

3. Ukkonen M, Kivivuori A, Starckjohann P, Lammi P, Junttila A, Panula V. Gallbladder‐related adverse events with semaglutide 2.4 mg: pooled analysis of placebo‐controlled STEP trials. Diabetes Obes Metab. 2026;28(10):9701-9703. doi:10.1111/dom.71087

4. FDA Adverse Event Monitoring System (AEMS) public dashboard for drugs and biologics. FDA. Accessed August 9, 2026. https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysishttps

5. Alvina, Jaffar H, Onwuzo CN, Chaar A, Eisa M. Differential biliary adverse event signals among GLP-1 receptor agonists: a FAERS disproportionality analysis. Dig Dis Sci. 2026;71(10):4703-4708. doi:10.1007/s10620-026-10017-5

6. Tao C, Zhang Y, Wan T, et al. Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database. Front Pharmacol. 2025;16:1557691. doi:10.3389/fphar.2025.1557691

7. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases. JAMA Intern Med. 2022;182(5):513-519. doi:10.1001/jamainternmed.2022.0338

8. Jones MW, Weir CB, Marietta M. Gallstones (Cholelithiasis). In: StatPearls. StatPearls Publishing; 2026. Accessed August 18, 2026. https://www.ncbi.nlm.nih.gov/books/NBK459370/

9. Parra-Landazury NM, Cordova-Gallardo J, Méndez-Sánchez N. Obesity and gallstones. Visc Med. 2021;37(5):394-402. doi:10.1159/000515545

10. Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025;138(6):934-940. doi:10.1016/j.amjmed.2025.01.021

11. Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol. 2013;304(10):G940-G948. doi:10.1152/ajpgi.00398.2012

12. Nexøe‐Larsen CC, Sørensen PH, Hausner H, et al. Effects of liraglutide on gallbladder emptying: a randomized, placebo‐controlled trial in adults with overweight or obesity. Diabetes Obes Metab. 2018;20(11):2557-2564. doi:10.1111/dom.13420

13. Nerild HH, Brønden A, Gether IM, et al. Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility. Diabetes Obes Metab. 2023;25(6):1632-1637. doi:10.1111/dom.15017

14. Rehfeld JF, Knop FK, Asmar A, Madsbad S, Holst JJ, Asmar M. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol. 2018;53(12):1429-1432. doi:10.1080/00365521.2018.1530297

15. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

16. Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44(3):765-773. doi:10.2337/dc20-1473

17. Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; Leader Publication Committee on behalf of the LEADER Trial Investigators. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care. 2019;42(10):1912-1920. doi:10.2337/dc19-0415

18. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892

19. Pak M, Lindseth G. Risk factors for cholelithiasis. Gastroenterol Nurs. 2016;39(4):297-309. doi:10.1097/SGA.0000000000000235

20. Stokes CS, Lammert F. Excess body weight and gallstone disease. Visc Med. 2021;37(4):254-260. doi:10.1159/000516418

21. Ghusn W, Hurtado MD. Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024;12:100127. doi:10.1016/j.obpill.2024.100127

22. Gigliotti L, Warshaw H, Evert A, et al. Incretin-based therapies and lifestyle interventions: the evolving role of registered dietitian nutritionists in obesity care. J Acad Nutr Diet. 2025;125(3):408-421. doi:10.1016/j.jand.2024.10.023

23. European Association for the Study of the Liver (EASL). EASL clinical practice guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146-181. doi:10.1016/j.jhep.2016.03.005

24. Diehl AK. Symptoms of gallstone disease. Baillieres Clin Gastroenterol. 1992;6(4):635-657. doi:10.1016/0950-3528(92)90044-F

25. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336-347. doi:10.1111/dom.12824